Purpose: To assess the success rates and complications of Densiron 68 intraocular tamponade in the management of complicated retinal detachment (RD) with proliferative vitreoretinopathy (PVR). Methods: Twenty-one eyes of 20 patients with complicated RD and PVR were included in this prospective study. Vitreoretinal surgery with Densiron 68 intraocular tamponade was performed in all patients. Results: The success rate with 1 operation using Densiron 68 was 85.7%, and with further surgery 90.5%. Visual acuity improved from a mean logMAR of 2.25 (SD 0.73) to 1.19 (SD 0.88), p = 0.0001. There was little evidence of dispersion and excessive inflammation. Conclusion: According to the results of this study, vitreoretinal surgery with temporary Densiron 68 intraocular tamponade appears to increase the anatomical success and improve visual acuity, while giving rise to minimal complications, in selected cases of complicated RD and PVR.

Keywords:
Visual acuity, Proliferative vitreoretinopathy, Retinal detachment
1.
Kirchhof B: Strategies to influence PVR development. Graefes Arch Clin Exp Ophthalmol 2004;242:699–703.
2.
Petersen J: The physical and surgical aspects of silicone oil: the vitreous cavity. Graefes Arch Clin Exp Ophthalmol 1988;225:452–456.
3.
Batman C, Cekic O: Effects of the long-term use of perfluoroperhydrophenanthrene on the retina. Ophthalmic Surg Lasers 1998;29:144–146.
4.
Vote B, Wheen L, Cluroe A, Teoh H, McGeorge A: Further evidence for proinflammtory nature of perfluorohexyloctane in the eye. Clin Experiment Ophthalmol 2003;31:408–414.
5.
Hiscott P, Magee RM, Colthurst M, Lois N, Wong D: Clinicopathological correlation of epiretinal membranes and posterior lens opacification following perfluorohexyloctane tamponade. Br J Ophthalmol 2001;85:179–183.
6.
Wetterqvist C, Wong D, Williams R, Stappler T, Herbert E, Freeburn S: Tamponade efficiency of perfluorohexyloctane and silicone oil solutions in a model eye chamber. Br J Ophthalmol 2004;88:692–696.
7.
Wong D, Van Meurs JC, Stappler T, Groenewald C, Pearce IA, McGalliard JN, Manousakis E, Herbert EN: A pilot study on the use of a perfluorohexyloctane/silicone oil solution as a heavier than water internal tamponade agent. Br J Ophthalmol 2005;89:662–665.
8.
Sandner D, Engelmann K: First experiences with high-density silicone oil (Densiron) as an intraocular tamponade in complex retinal detachment. Graefes Arch Clin Exp Ophthalmol 2006;244:609–619.
9.
Sandner D, Herbrig E, Engelmann K: High-density silicone oil (Densiron) as a primary intraocular tamponade: 12-month follow up. Graefes Arch Clin Exp Ophthalmol 2007;245:1097–1105.
10.
Joussen AM, Kirchhof B, Schrage N, Ocklenburg C, Hilgers RD; HSO Study Group: Heavy silicone oil versus standard silicone oil as vitreous tamponade in inferior PVR (HSO Study): design issues and implications. Acta Ophthalmol Scand 2007;85:623–630.
11.
Lucke K: Silikonöl in der Chirurgie komplizierter Netzhautablösungen. Ophthalmologe 1993;90:215–238.
12.
Wolf S, Schön V, Meier P, Wiedemann P: Silicone oil-RMN3 mixture (‘‘heavy silicone oil’’) as internal tamponade for complicated retinal detachment. Retina 2003;23:335–342.
13.
Tognetto D, Minutola D, Sanguinetti G, Ravalico G: Anatomical and functional outcomes after heavy silicone oil tamponade in vitreoretinal surgery for complicated retinal detachment: a pilot study. Ophthalmology 2005;112:1574.
14.
Kirchhof B, Wong D, Van Meurs J, Hilgers RD, Macek M, Lois N, Schrage NF: Use of perfluorohexyloctane as a long-term internal tamponade agent in complicated retinal detachment surgery. Am J Ophthalmol 2002;133:95–101.
15.
Rizzo S, Genovesi-Ebert F, Belting C: The combined use of perfluorohexyloctane (F6H8) and silicone oil as an intraocular tamponade in the treatment of severe retinal detachment. Graefes Arch Clin Exp Ophthalmol 2006;244:709–716.
16.
Gerding H, Kolck A: Perfluorohexyloctane as internal tamponade in patients with complicated retinal detachment: results after 6 months (in German). Ophthalmologe 2004;101:255–262.
17.
Hoerauf H, Roider J, Kobuch K, Laqua H: Perfluorohexylethan (O62) as ocular endotamponade in complex vitreoretinal surgery. Retina 2005;25:479–488.
18.
Rizzo S, Genovesi-Ebert F, Vento A, Cresti F, Di Bartolo E, Belting C: A new heavy silicone oil (HWS 46-3000) used as a prolonged internal tamponade agent in complicated vitreoretinal surgery: a pilot study. Retina 2007;27:613–620.
19.
Rizzo S, Genovesi-Ebert F, Belting C, Vento A, Cresti F: A pilot study on the use of silicone oil – RMN3 as heavier-than-water endotamponade agent. Graefes Arch Clin Exp Ophthalmol 2005;243:1153–1157.
20.
Rizzo S, Genovesi-Ebert F, Belting C, Foltran F, Gandolfo E, Lesnoni G, Dell’omo E, Zenoni S, Azzolini M, De Molfetta V: Long-term vitreous replacement with perfluorohexyloctane and silicone oil: preliminary reports of a multicentric study. Ophthalmologica 2005;219:147–153.
21.
Roider J, Hoerauf H, Kobuch K, Gabel VP: Clinical findings on the use of long-term heavy tamponades (semifluorinated alkanes and their oligomers) in complicated retinal detachment surgery. Graefes Arch Clin Exp Ophthalmol 2002;240:965–971.
22.
Herbrig E, Sandner D, Engelmann K: Anatomical and functional results of endotamponade with heavy silicone oil – Densiron 68 – in complicated retinal detachment. Ophthalmic Res 2007;39:198–206.
23.
Majid MA, Hussin HM, Biswas S, Haynes RJ, Mayer EJ, Dick AD: Emulsification of Densiron-68 used in inferior retinal detachment surgery. Eye 2008;22:152–157.
24.
Stefaniotou MI, Aspiotis MV, Kitsos GD, Kalogeropoulos CD, Asproudis IC, Psilas KG: Our experience with perfluorohexyloctane (F6H8) as a temporary endotamponade in vitreoretinal surgery. Eur J Ophthalmol 2002;12:518–522.
25.
Martinez-Castillo V, Zapata MA, Boixadera A, Fonollosa A, Garcia-Arumi J: Pars plana vitrectomy, laser retinopexy, and aqueous tamponade for pseudophakic rhegmatogenous retinal detachment. Ophthalmology 2007;114:297–302.
26.
Tanner V, Minihan M, Williamson TH: Management of inferior retinal breaks during pars plana vitrectomy for retinal detachment. Br J Ophthalmol 2001;85:480–482.
27.
Abrams GW, Azen SP, McCuen II BW, Flynn HW Jr, Lai MY, Ryan SJ: Vitrectomy with silicone oil or long-acting gas in eyes with severe proliferative vitreoretinopathy: results of additional and long-term follow-up. Silicone Study report 11. Arch Ophthalmol 1997;115:335–344.
28.
Quiram PA, Gonzales CR, Hu W, Gupta A, Yoshizumi MO, Kreiger AE, Schwartz SD: Outcomes of vitrectomy with inferior retinectomy in patients with recurrent rhegmatogenous retinal detachments and proliferative vitreoretinopathy. Ophthalmology 2006;113:2041–2047.
29.
Wong D, Cazabon S, Ali H, Kumar I, Valldeperas X, Groenewald C, Pearce I: Can the sequential use of conventional silicone oil and heavy oil be a strategy for the management of proliferative vitreoretinopathy? Ann Acad Med Singapore 2006;35:181–184.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.